Company Profile
Merus Stock Price, News & Catalysts
- Ticker:
- MRUS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands
Why the stock is moving
Current closing-price context is not available for MRUS.
Company overview
Business overview
Merus is a clinical-stage antibody company focused on precision oncology and bispecific antibody development. Its platform is built around engineered immunology and cancer programs.
Geographic Base and Sector Classification
Headquartered in the Netherlands and listed on NASDAQ as an ADR, Merus has a global biotechnology footprint.
Business Model Characteristics
The business depends on clinical data, platform validation, and the ability to create differentiated oncology assets.
Position Within the Biotechnology Landscape
Merus is a platform antibody name with meaningful upside if its bispecific science keeps validating clinically.
Future catalysts
- Merus's catalysts are petosemtamab and zenocutuzumab, with the next data updates deciding whether the bispecific oncology story keeps strengthening. The company still needs the next readout to make the platform feel more than promising.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Merus do?
Merus is a clinical-stage antibody company focused on precision oncology and bispecific antibody development. Its platform is built around engineered immunology and cancer programs.
On which exchange is MRUS stock listed?
Merus (MRUS) is associated with NASDAQ, Netherlands, Biopharma.
What is petosemtamab?
Merus's catalysts are petosemtamab and zenocutuzumab, with the next data updates deciding whether the bispecific oncology story keeps strengthening.
Which conditions is Merus targeting with petosemtamab?
Merus is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Merus describe recent progress with petosemtamab?
Merus's catalysts are petosemtamab and zenocutuzumab, with the next data updates deciding whether the bispecific oncology story keeps strengthening.
What is zenocutuzumab?
Merus's catalysts are petosemtamab and zenocutuzumab, with the next data updates deciding whether the bispecific oncology story keeps strengthening.
What should investors watch for with zenocutuzumab?
Merus's catalysts are petosemtamab and zenocutuzumab, with the next data updates deciding whether the bispecific oncology story keeps strengthening.
What is Merus?
Merus is a clinical-stage antibody company focused on precision oncology and bispecific antibody development.